Biogen soars 64% after FDA approves first new Alzheimer's drug in 18 years
AP Photo/Steven Senne Biogen soared as much as 64% on Monday after the US FDA approved the company's Alzheimer's treatment. The approval marks the first new Alzheimer's disease treatment in nearly two decades. An FDA advisory committee in November last year had concluded the drug did not effectively treat the disease. Sign up here for our daily newsletter, 10 Things […]
Read more